If this release from MT Pharma America on its new amyotrophic laterals sclerosis (ALS) drug had provided a clear enumeration of the benefits of the drug, cost information, and some explanation of any conflicts of interest in the physician being quoted, it would be a solid release. In many ways, this release provides good information for reporters or even the general public. It follows the same basic tenets of most television pharmaceutical ads in that it hews to the evidence used to clear FDA hurdles and provides an ample list of side effects.
ALS is a progressive neurological disorder with limited treatment options, none of which cure the disease. It belongs within a wider group of conditions known as motor neuron diseases that are caused by gradual deterioration and death of motor neurons, or nerve cells. The Centers for Disease Control and Prevention (CDC) estimated that between 14,000 and 15,000 Americans had ALS in 2016. “Currently, there is no cure for ALS and no effective treatment to halt, or reverse, the progression of the disease, ” according to the National Institute of Neurological Disorders and Stroke (NINDS). The existing drug, Rilutek, has shown in clinical trials that it can extend life by a few months, and the newly approved drug described here, Radicava, was shown to slow decline in daily functioning. With so few treatment options available, the new drug is being welcomed as another option among very limited offerings.
It’s almost as if a sentence is missing from the release. It does not say that the drug is expensive or inexpensive, but one must presume that it is expensive because it goes into some detail about a program set up to help people afford the drug. It says, “MTPharma America is helping to make RADICAVA accessible to all patients who need it and has created Searchlight Support, a patient access program for people with ALS who are prescribed RADICAVA. As soon as a person receives a prescription, he or she can access Searchlight Support, including personal case management, reimbursement support and 24/7 clinical support. Some people with ALS who have received prescriptions for RADICAVA may be eligible to receive additional assistance from MTPharma America.”
According to the ALS Association, “The drug’s list price is $1K per infusion, $11K per dosage cycle, which amounts to $146K per year. This does not take into account coverage from insurance or Medicare/Medicaid.”
The story does put some numbers to the benefits, but they are in relative terms and not easy to understand.
“The pivotal Phase 3 study (MCI186-19), which evaluated 137 people with ALS, formed the basis for the FDA approval of RADICAVA. Data demonstrated patients who received RADICAVA for six months experienced significantly less decline in physical function —by 33 percent or 2.49 ALSFRS-R points (p=0.0013).”
Although the release rightly states that the intervention improved patient outcomes by 2.49 ALSFRS-R points, there is no discussion about what this means in terms of actual patient function. A change of two and a half points might just equate to a patient not developing worse handwriting and excess saliva. These changes may be important but are minimal with respect to the degree of disability the disease causes. A statement that no change in mortality or independent living has been seen would also have been warranted.
We would also liked to have seen a clear numerical comparison. How many of the 137 received Radicava for six months? How many of those patients saw a significant preservation of physical function? How many saw no benefit?
The release does provide a rather long list of potential harms. And then it goes on to say, “These are not all the possible side effects of Radicava. Call your healthcare provider for medical advice about side effects. You may report side effects to MT Pharma America, Inc. at 1-888-292-0058 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.”
We’re giving it a pass here because it explains quite a bit about the study. It would have been better had it also explained whether the findings had been published in a peer-reviewed journal or undergone any other outside vetting.
There is no disease mongering in the release. It also provides some context about the prevalence of ALS.
The release is a corporate release. And it’s clear that the drug company that makes the drug in question is hoping to sell the drug. There are two things that are unclear, though. First, the relationship of the only physician quoted in the article to the drug or the company. Second, the relationship of Barbara Newhouse, president and CEO, ALS Association, to the company. Both basically give the findings a lot of fanfare. And Newhouse in particular provides a very positive take by talking about the potential impact on patients, saying.“We applaud the work MT Pharma America and the FDA are doing as they have taken unprecedented steps to get this treatment into the hands of patients as quickly as possible.” Drug companies often sponsor patient support organizations such as the ALS Association. For example, in 2016, the ALS Association announced MT Pharma as a “corporate sponsor” of its walk to raise money for disease research.
There is no comparison to alternatives in the release. As Jeff Akst at The Scientist pointed out there, is one other drug on the market, “The drug, manufactured by MT Pharma America, the US subsidiary of the Japanese company Mitsubishi Tanabe Pharma Corporation, is only the second approved ALS treatment in the U.S. The first, riluzole (Rilutek), was approved in December 1995.”
The release makes it clear that the drug is only now approved for prescription in the U.S. after having been on the market in Japan and South Korea. It says, “Edaravone was discovered and developed for ALS by Mitsubishi Tanabe Pharma Corporation (MTPC) and will be commercialized in the U.S. by MT Pharma America. MTPC group companies began researching ALS in 2001 through a comprehensive clinical platform over a 13-year period. In 2015, edaravone was approved for use as a treatment for ALS in Japan and South Korea.”
The release establishes the novelty of the findings in that this is the first new drug for treating ALS in more than 20 years.
There is no unjustifiable language in the release.
Systematic, Criteria-Driven
We’ve written about the hype of liquid biopsies for years (see link in comment below). And now this…. https://www.statnews.com/2022/01/12/medicare-shouldnt-cover-liquid-biopsies-early-cancer-detection/
Case counts still matter. “(There) are stories that may not be told adequately if only hospitalizations and deaths are emphasized.” @garyschwitzer interviewed by @dbauder of @AP. https://apnews.com/article/omicron-changing-news-outlets-covid-data-da9272f7c4c8a109c3bfb56bed9e9c76
My friend Gary @garyschwitzer wrote to his city council representative in a Minnesota town about a Viva Las Vegas event scheduled for January.
The response he got seems to perfectly capture where we are now.
https://www.healthnewsreview.org/2021/12/2021-ends-with-covid-craziness-in-sports-and-politics/
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like